Immix Biopharma Capital Raise of $125M
Immix Biopharma priced an underwritten public offering of 11,363,637 shares of common stock at $11.00 per share, generating gross proceeds of $125 million. The company intends to use the net proceeds to fund the development of its CAR-T cell therapy NXC-201, working capital, and general corporate purposes.
- Value
- $125M
- Counterparty
- J.P. Morgan Securities LLC